Utility of Commonly Used Commercial Human Chorionic Gonadotropin Immunoassays in the Diagnosis and Management of Trophoblastic Diseases
Open Access
- 1 February 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (2) , 308-315
- https://doi.org/10.1093/clinchem/47.2.308
Abstract
Background: Patients with trophoblastic diseases produce ordinary and irregular forms of human chorionic gonadotropin (hCG; e.g., nicked hCG, hCG missing the β-subunit C-terminal segment, hyperglycosylated hCG, and free β subunit) that are recognized to differing extents by automated immunometric hCG (or hCGβ) assays. This has led to low or false-negative results and misdiagnosis of persistent disease. False-positive hCG immunoreactivity has also been detected, leading to needless therapy for trophoblastic diseases. Here we compare seven commonly used hCG assays. Methods: Standards for five irregular forms hCG produced in trophoblastic diseases, serum samples from 59 patients with confirmed trophoblastic diseases, and serum samples from 12 women with previous false-positive hCG results (primarily in the Abbott AxSYM assay) were blindly tested by commercial laboratories in the Beckman Access hCGβ, the Abbott AxSYM hCGβ, the Chiron ACS:180 hCGβ, the Baxter Stratus hCG test, the DPC Immulite hCG test, the Serono MAIAclone hCGβ tests, and in the hCGβ RIA. Results: Only the RIA and the DPC appropriately detected the five irregular hCG standards. Only the Beckman, DPC, and Abbott assays gave results similar to the RIA in the patients with confirmed trophoblastic diseases (values within 25% of RIA in 49, 49, and 54 of 59 patients, respectively). For samples that were previously found to produce false-positive hCG results, no false-positive results were detected with the DPC and Chiron tests (5 samples, median 10 IU/L) in the Beckman (1 of 5), Serono (2 of 9), and Baxter assays (1 of 5), and the hCGβ RIA (3 of 9; median for all assays, Conclusions: Of six frequently used hCG immunometric assays, only the DPC detected the five irregular forms of βhCG, agreed with the RIA, and avoided false-positive results in the samples tested. This assay, and similarly designed assays not tested here, seem appropriate for hCG testing in the diagnosis and management of trophoblastic diseases.Keywords
This publication has 13 references indexed in Scilit:
- False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrationsThe Lancet, 2000
- Hyperglycosylated Human Chorionic Gonadotropin (Invasive Trophoblast Antigen) Immunoassay: A New Basis for Gestational Down Syndrome ScreeningClinical Chemistry, 1999
- Following Metastatic Placental Site Trophoblastic Tumor with Urine β-Core FragmentGynecologic Oncology, 1999
- False-Positive hCG Assay Results Leading to Unnecessary Surgery and Chemotherapy and Needless Occurrences of Diabetes and ComaClinical Chemistry, 1999
- Phantom hCG and Phantom ChoriocarcinomaGynecologic Oncology, 1998
- Immunoassay of human chorionic gonadotropin, its free subunits, and metabolitesClinical Chemistry, 1997
- Carbohydrate and peptide structure of the α- and β-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinomaEndocrine, 1997
- Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping controlClinical Chemistry, 1997
- Pseudohypergonadotropinemia and pseudohyperprolactinemia induced by heterophilic antibodies?Journal of Molecular Medicine, 1984
- INTERNATIONAL REFERENCE PREPARATION OF HUMAN CHORIONIC GONADOTROPHIN FOR IMMUNOASSAY: POTENCY ESTIMATES IN VARIOUS BIOASSAY AND PROTEIN BINDING ASSAY SYSTEMS; AND INTERNATIONAL REFERENCE PREPARATIONS OF THE α AND β SUBUNITS OF HUMAN CHORIONIC GONADOTROPHIN FOR IMMUNOASSAYJournal of Endocrinology, 1980